Bank of America just raised its EUR/USD forecast
CAMBRIDGE, MA—Nicaise Claude, a director at Sarepta Therapeutics, Inc. (NASDAQ:SRPT), recently sold 2,491 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission dated March 12, 2025. The shares were sold at a weighted average price of approximately $99.64, resulting in a total transaction value of $248,203. The transaction comes as the stock trades near its 52-week low of $97.11, according to InvestingPro data.
The sale was part of a series of transactions that also included the exercise of stock options. Claude exercised options to acquire 9,746 shares at a price of $25.18 per share, a transaction valued at $245,404. Following these transactions, Claude’s direct ownership stands at 27,812 shares.
The stock sale was conducted to cover the exercise price of the expiring options, as per the details provided in the filing. The shares sold were part of multiple transactions priced between $99.64 and $99.87.
Sarepta Therapeutics, based in Cambridge, Massachusetts, specializes in pharmaceutical preparations, focusing on developing genetic medicine for rare diseases. The company, currently valued at $9.55 billion, has demonstrated robust growth with revenue reaching $1.9 billion, representing a 53% year-over-year increase. For deeper insights into SRPT’s valuation and growth prospects, access the comprehensive research report available on InvestingPro.
In other recent news, Sarepta Therapeutics reported impressive financial results for Q4 2024, with earnings per share of $1.9, surpassing the forecast of $1.54. The company’s revenue reached $658.4 million, exceeding expectations of $589.45 million, marking a 75% year-over-year increase. Mizuho (NYSE:MFG) Securities, after reviewing the company’s strong fourth-quarter performance, adjusted Sarepta’s price target from $195 to $190 while maintaining an Outperform rating. RBC Capital also made adjustments, lowering the price target to $161 from $165 but reiterated an Outperform rating, noting the potential for Sarepta to exceed sales forecasts for its product Elevidys.
Cantor Fitzgerald maintained an Overweight rating on Sarepta with a price target of $163, reflecting confidence in the company’s financial outlook and alignment with its guidance. Meanwhile, Scotiabank (TSX:BNS) initiated coverage on Sarepta with a Sector Perform rating and a price target of $105, acknowledging the successful launch of the Elevidys gene therapy but expressing caution about future market challenges. Analysts from various firms highlighted the significant growth potential for Sarepta’s products, particularly Elevidys, which has reached less than 5% of eligible Duchenne muscular dystrophy patients, indicating substantial room for market expansion.
Sarepta’s future projections remain optimistic, with the company forecasting net product revenue for 2025 between $2.9 billion and $3.1 billion, representing a 70% increase. As the company continues to focus on its gene therapy pipeline and potential blockbuster launches, investors and analysts are closely monitoring these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.